Abstract P2001: Nicotinamide Riboside the New Promising Drug of Myocardial Infarction Management
| العنوان: | Abstract P2001: Nicotinamide Riboside the New Promising Drug of Myocardial Infarction Management |
|---|---|
| المؤلفون: | Rana Ghali, Abdo Jurjus, Mathias Mericskay, Nada J Habeichi, Fouad A. Zouein, Marwan M. Refaat, Cynthia Tannous |
| المصدر: | Hypertension. 74 |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health), 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Drug, biology, business.industry, media_common.quotation_subject, Metabolism, Pharmacology, medicine.disease, Cofactor, chemistry.chemical_compound, chemistry, Fibrosis, Nicotinamide riboside, Internal Medicine, biology.protein, Medicine, NAD+ kinase, Myocardial infarction, business, media_common, Cause of death |
| الوصف: | Introduction: Myocardial infarction (MI) is the major cause of death worldwide. Nicotinamide-Adenine-Dinucleotide (NAD) is emerging as a metabolic target being a major coenzyme in mitochondrial oxidation and oxidative phosphorylation and a substrate of Sirtuins and PARPs, critical enzymes for cardiac remodeling. Altered NAD homeostasis is reported in several models of heart failure including MI with a striking upregulation of Nicotinamide-Riboside-Kinase2 (NMRK2) and a decrease of NAD levels. NMRK2 requires Nicotinamide Riboside (NR) as a substrate to produce NAD. In this study, we hypothesized that stimulating NMRK2 pathway by NR supplementation will upregulate NAD synthesis and subsequently improve metabolic state and cardiac function post-MI. Methods: MI was induced by the left anterior descending coronary artery ligation in 2-3 months old male mice. Echocardiography was performed at baseline, day 1, and day 4 following MI. At sacrifice, cardiac genes expression was evaluated by RT-qPCR and myocardial NAD levels were determined using a colorimetric assay. Histologically, Masson-Trichrome was performed on cardiac sections to assess cardiac fibrosis. Results: RT-qPCR analysis showed a 60 fold increase of Nmrk2 expression levels (P&it0.01) 4 days following MI. This upregulation was highlighted by the boost of NAD levels (708.81±79.83 pmoles/g of tissue in the MI-NR group vs 394.12 ±84.04 pmoles/g of tissue in the control group (p&it0.05)). Following MI, mitochondrial SIRT3 expression dropped by 40% and NR restored those levels which are critical for mitochondrial biogenesis. NR treatment markedly decreased the expression of PARP1 (1.22±0.34 in MI-NR group vs 2.69±0.45 in MI group (p&it0.05)), a well-known consumer of NAD. Histologically, fibrosis levels significantly dropped 4 days following NR treatment when compared to non-treated MI group (11±2,72 u.a vs 18±1,98 u.a, p&it0.05). Conclusion: NR treatment improves myocardial metabolic impairment, but not myocardial function, as early as 4 days following MI when compared to relative control groups. Additional experiments are underway to reveal the impact of NR treatment on cardiac remodeling and function at 7 days post-MI. |
| تدمد: | 1524-4563 0194-911X |
| DOI: | 10.1161/hyp.74.suppl_1.p2001 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::7beec53fb7156b01caac7315aa74d28d https://doi.org/10.1161/hyp.74.suppl_1.p2001 |
| رقم الانضمام: | edsair.doi...........7beec53fb7156b01caac7315aa74d28d |
| قاعدة البيانات: | OpenAIRE |
| ResultId |
1 |
|---|---|
| Header |
edsair OpenAIRE edsair.doi...........7beec53fb7156b01caac7315aa74d28d 831 3 unknown 830.794311523438 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........7beec53fb7156b01caac7315aa74d28d&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://explore.openaire.eu/search/publication?articleId=doi_________::7beec53fb7156b01caac7315aa74d28d# [Name] => EDS - OpenAIRE [Category] => fullText [Text] => View record in OpenAIRE [MouseOverText] => View record in OpenAIRE ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Abstract P2001: Nicotinamide Riboside the New Promising Drug of Myocardial Infarction Management
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Rana+Ghali%22">Rana Ghali</searchLink><br /><searchLink fieldCode="AR" term="%22Abdo+Jurjus%22">Abdo Jurjus</searchLink><br /><searchLink fieldCode="AR" term="%22Mathias+Mericskay%22">Mathias Mericskay</searchLink><br /><searchLink fieldCode="AR" term="%22Nada+J+Habeichi%22">Nada J Habeichi</searchLink><br /><searchLink fieldCode="AR" term="%22Fouad+A%2E+Zouein%22">Fouad A. Zouein</searchLink><br /><searchLink fieldCode="AR" term="%22Marwan+M%2E+Refaat%22">Marwan M. Refaat</searchLink><br /><searchLink fieldCode="AR" term="%22Cynthia+Tannous%22">Cynthia Tannous</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => <i>Hypertension</i>. 74 ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Ovid Technologies (Wolters Kluwer Health), 2019. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2019 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Drug%22">Drug</searchLink><br /><searchLink fieldCode="DE" term="%22biology%22">biology</searchLink><br /><searchLink fieldCode="DE" term="%22business%2Eindustry%22">business.industry</searchLink><br /><searchLink fieldCode="DE" term="%22media%5Fcommon%2Equotation%5Fsubject%22">media_common.quotation_subject</searchLink><br /><searchLink fieldCode="DE" term="%22Metabolism%22">Metabolism</searchLink><br /><searchLink fieldCode="DE" term="%22Pharmacology%22">Pharmacology</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edisease%22">medicine.disease</searchLink><br /><searchLink fieldCode="DE" term="%22Cofactor%22">Cofactor</searchLink><br /><searchLink fieldCode="DE" term="%22chemistry%2Echemical%5Fcompound%22">chemistry.chemical_compound</searchLink><br /><searchLink fieldCode="DE" term="%22chemistry%22">chemistry</searchLink><br /><searchLink fieldCode="DE" term="%22Fibrosis%22">Fibrosis</searchLink><br /><searchLink fieldCode="DE" term="%22Nicotinamide+riboside%22">Nicotinamide riboside</searchLink><br /><searchLink fieldCode="DE" term="%22Internal+Medicine%22">Internal Medicine</searchLink><br /><searchLink fieldCode="DE" term="%22biology%2Eprotein%22">biology.protein</searchLink><br /><searchLink fieldCode="DE" term="%22Medicine%22">Medicine</searchLink><br /><searchLink fieldCode="DE" term="%22NAD%2B+kinase%22">NAD+ kinase</searchLink><br /><searchLink fieldCode="DE" term="%22Myocardial+infarction%22">Myocardial infarction</searchLink><br /><searchLink fieldCode="DE" term="%22business%22">business</searchLink><br /><searchLink fieldCode="DE" term="%22media%5Fcommon%22">media_common</searchLink><br /><searchLink fieldCode="DE" term="%22Cause+of+death%22">Cause of death</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Introduction: Myocardial infarction (MI) is the major cause of death worldwide. Nicotinamide-Adenine-Dinucleotide (NAD) is emerging as a metabolic target being a major coenzyme in mitochondrial oxidation and oxidative phosphorylation and a substrate of Sirtuins and PARPs, critical enzymes for cardiac remodeling. Altered NAD homeostasis is reported in several models of heart failure including MI with a striking upregulation of Nicotinamide-Riboside-Kinase2 (NMRK2) and a decrease of NAD levels. NMRK2 requires Nicotinamide Riboside (NR) as a substrate to produce NAD. In this study, we hypothesized that stimulating NMRK2 pathway by NR supplementation will upregulate NAD synthesis and subsequently improve metabolic state and cardiac function post-MI. Methods: MI was induced by the left anterior descending coronary artery ligation in 2-3 months old male mice. Echocardiography was performed at baseline, day 1, and day 4 following MI. At sacrifice, cardiac genes expression was evaluated by RT-qPCR and myocardial NAD levels were determined using a colorimetric assay. Histologically, Masson-Trichrome was performed on cardiac sections to assess cardiac fibrosis. Results: RT-qPCR analysis showed a 60 fold increase of Nmrk2 expression levels (P&it0.01) 4 days following MI. This upregulation was highlighted by the boost of NAD levels (708.81±79.83 pmoles/g of tissue in the MI-NR group vs 394.12 ±84.04 pmoles/g of tissue in the control group (p&it0.05)). Following MI, mitochondrial SIRT3 expression dropped by 40% and NR restored those levels which are critical for mitochondrial biogenesis. NR treatment markedly decreased the expression of PARP1 (1.22±0.34 in MI-NR group vs 2.69±0.45 in MI group (p&it0.05)), a well-known consumer of NAD. Histologically, fibrosis levels significantly dropped 4 days following NR treatment when compared to non-treated MI group (11±2,72 u.a vs 18±1,98 u.a, p&it0.05). Conclusion: NR treatment improves myocardial metabolic impairment, but not myocardial function, as early as 4 days following MI when compared to relative control groups. Additional experiments are underway to reveal the impact of NR treatment on cardiac remodeling and function at 7 days post-MI. ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1524-4563<br />0194-911X ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1161/hyp.74.suppl_1.p2001 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_________::7beec53fb7156b01caac7315aa74d28d" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_________::7beec53fb7156b01caac7315aa74d28d</link><br /><link linkTarget="URL" linkTerm="https://doi.org/10.1161/hyp.74.suppl_1.p2001" linkWindow="_blank">https://doi.org/10.1161/hyp.74.suppl_1.p2001</link> ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi...........7beec53fb7156b01caac7315aa74d28d ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1161/hyp.74.suppl_1.p2001
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => Undetermined
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Drug
[Type] => general
)
[1] => Array
(
[SubjectFull] => biology
[Type] => general
)
[2] => Array
(
[SubjectFull] => business.industry
[Type] => general
)
[3] => Array
(
[SubjectFull] => media_common.quotation_subject
[Type] => general
)
[4] => Array
(
[SubjectFull] => Metabolism
[Type] => general
)
[5] => Array
(
[SubjectFull] => Pharmacology
[Type] => general
)
[6] => Array
(
[SubjectFull] => medicine.disease
[Type] => general
)
[7] => Array
(
[SubjectFull] => Cofactor
[Type] => general
)
[8] => Array
(
[SubjectFull] => chemistry.chemical_compound
[Type] => general
)
[9] => Array
(
[SubjectFull] => chemistry
[Type] => general
)
[10] => Array
(
[SubjectFull] => Fibrosis
[Type] => general
)
[11] => Array
(
[SubjectFull] => Nicotinamide riboside
[Type] => general
)
[12] => Array
(
[SubjectFull] => Internal Medicine
[Type] => general
)
[13] => Array
(
[SubjectFull] => biology.protein
[Type] => general
)
[14] => Array
(
[SubjectFull] => Medicine
[Type] => general
)
[15] => Array
(
[SubjectFull] => NAD+ kinase
[Type] => general
)
[16] => Array
(
[SubjectFull] => Myocardial infarction
[Type] => general
)
[17] => Array
(
[SubjectFull] => business
[Type] => general
)
[18] => Array
(
[SubjectFull] => media_common
[Type] => general
)
[19] => Array
(
[SubjectFull] => Cause of death
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Abstract P2001: Nicotinamide Riboside the New Promising Drug of Myocardial Infarction Management
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Rana Ghali
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Abdo Jurjus
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Mathias Mericskay
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Nada J Habeichi
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Fouad A. Zouein
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Marwan M. Refaat
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Cynthia Tannous
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 09
[Type] => published
[Y] => 2019
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 15244563
)
[1] => Array
(
[Type] => issn-print
[Value] => 0194911X
)
[2] => Array
(
[Type] => issn-locals
[Value] => edsair
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 74
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Hypertension
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |